PDF(Pubmed)
Abstract：
Mesenchymal epithelial transition (MET) factor alteration in non-small cell lung cancer (NSCLC) includes MET exon 14 skipping alteration (METex14 skipping), MET gene amplification, MET gene mutation (mainly kinase domain mutation), MET gene fusion, and MET protein overexpression. The incidence of METex14 skipping in patients with NSCLC is 0.9-4.0%. At present, drugs targeting METex14 skipping have been approved in China and other countries like Japan and USA. Patients with advanced NSCLC should undergo testing, including METex14 skipping, to screen the population with benefit from targeted therapy with MET inhibitors. The incidence of de novo MET gene amplification in NSCLC patients is 1-5%, the incidence of acquired MET gene amplification in epidermal growth factor receptor tyrosine kinase inhibitor (TKI)-resistant patients is 5-50%, and the incidence in anaplastic lymphoma kinase (ALK) TKI-resistant patients is about 13%; the incidence of MET protein overexpression in NSCLC patients is 13.7-63.7%. Several clinical trials on MET gene amplification and MET protein overexpression are ongoing, which have demonstrated their important guiding significance as biomarkers in the clinical treatment with MET inhibitors. Accurate detection of MET alterations is a prerequisite for MET inhibitor therapy. Since there are many types of MET alterations and related testing methods, as well as many problems and challenges during clinical testing, further sorting and standardization are required. Combined with clinical practice experience, literature review, and expert discussion, the writing group developed this consensus on the three main types of MET alterations (METex14 skipping, MET gene amplification, and MET protein overexpression) in order to guide the practical applications of clinical MET testing.
摘要：
非小细胞肺癌（NSCLC）中的间充质上皮转化（MET）因子改变包括MET外显子14跳跃改变（METex14跳跃），MET基因扩增,MET基因突变（主要是激酶结构域突变），MET基因融合,和MET蛋白过表达。非小细胞肺癌患者METex14跳跃的发生率为0.9-4.0%。目前,针对METex14跳过的药物已在中国和日本和美国等国家获得批准。晚期NSCLC患者应接受检测，包括METex14跳绳，筛选受益于MET抑制剂靶向治疗的人群。在NSCLC患者中，从头MET基因扩增的发生率为1-5%，表皮生长因子受体酪氨酸激酶抑制剂(TKI)耐药患者获得性MET基因扩增的发生率为5-50%,间变性淋巴瘤激酶（ALK）TKI耐药患者的发生率约为13％；NSCLC患者中MET蛋白过表达的发生率为13.7-63.7％。一些关于MET基因扩增和MET蛋白过表达的临床试验正在进行中，MET抑制剂作为生物标志物在临床治疗中的重要指导意义。MET改变的准确检测是MET抑制剂治疗的先决条件。由于有许多类型的MET改变和相关的测试方法，以及临床试验中的许多问题和挑战，需要进一步分类和标准化。结合临床实践经验,文献综述，和专家讨论，写作小组就MET改变的三种主要类型达成了共识(METex14跳过，MET基因扩增,和MET蛋白过表达），以指导临床MET检测的实际应用。
